Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Vaccine Production01:23

Vaccine Production

129
Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...
129
Vaccinations01:51

Vaccinations

43.9K
Overview
43.9K
Vaccines01:21

Vaccines

86
Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the...
86
Cross-reactivity00:42

Cross-reactivity

28.7K
Overview
28.7K
Humoral Immune Responses01:36

Humoral Immune Responses

65.8K
Overview
65.8K
Hybridoma Technology01:31

Hybridoma Technology

13.1K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
13.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Why Is Mumps Vaccine not Persistently Effective?

The Pediatric infectious disease journal·2026
Same author

Chikungunya: Unpronounceable, But Important.

The Pediatric infectious disease journal·2026
Same author

Why do we have a vaccine for measles, but not cytomegalovirus (CMV)?

PLoS pathogens·2026
Same author

A Vaccine to Prevent Congenital Cytomegalovirus: Where Do We Go Next?

JAMA pediatrics·2026
Same author

Smallpox Is Gone, but Not Forgotten.

The Pediatric infectious disease journal·2026
Same author

Evidence for the Effectiveness of COVID-19 Vaccine in Children.

The Pediatric infectious disease journal·2026
Same journal

Author Correction: An atlas of genetic effects on cellular composition of the tumor microenvironment.

Nature immunology·2026
Same journal

Exhausted CD8<sup>+</sup> T cell fate is programmed by dynamic CTCF-mediated enhancer activation and invariant CTCF-imposed barriers.

Nature immunology·2026
Same journal

Mapping self-associating chromatin hubs identifies Id proteins as key determinants of exhausted CD8<sup>+</sup> T cell fate.

Nature immunology·2026
Same journal

Exhausted CD8<sup>+</sup> T cell subsets differ a TAD.

Nature immunology·2026
Same journal

Pregnancy-induced tissue-resident memory-like T cells contribute to tumor control in breast cancer.

Nature immunology·2026
Same journal

Mechanosensing by T cells promotes a tissue-resident memory transcriptional program.

Nature immunology·2026
See all related articles

Related Experiment Video

Updated: Apr 28, 2026

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection
12:09

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection

Published on: May 2, 2011

42.3K

Toward a human vaccines project

Wayne C Koff1, Ian D Gust2, Stanley A Plotkin3

  • 1International AIDS Vaccine Initiative, New York, New York, USA.

Nature Immunology
|June 19, 2014
PubMed
Summary

No abstract available in PubMed .

More Related Videos

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells
10:03

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells

Published on: August 1, 2013

16.3K
Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches
13:36

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches

Published on: May 6, 2015

10.0K

Related Experiment Videos

Last Updated: Apr 28, 2026

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection
12:09

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection

Published on: May 2, 2011

42.3K
Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells
10:03

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells

Published on: August 1, 2013

16.3K
Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches
13:36

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches

Published on: May 6, 2015

10.0K